- In patients with type 2 diabetes mellitus (T2DM), empagliflozin (10 or 25 mg) + linagliptin 5mg demonstrated superior efficacy and similar safety in achieving euglycemia compared with empagliflozin (10 or 25 mg) or linagliptin 5mg monotherapies.
Why this matters
- Fixed-dose empagliflozin plus linagliptin may simplify the drug dosing regimen, reduce pill burden and enhance treatment adherence; hence, it may be an important therapeutic option in patients with T2DM during routine clinical practice.
- 6 randomised controlled trials (RCTs) including 2857 patients with T2DM met eligibility criteria.
- Funding: None.
- After 24 weeks, empagliflozin 10 mg plus linagliptin 5 mg vs either drug alone had significant reductions in:
- haemoglobin A1c level (HbA1c; weighted mean difference [WMD], −0.72%, 95% CI, −1.04 to −0.40%; I2=90.0%);
- weight (WMD, −2.08 [95% CI, −2.62 to −1.53] kg; I2=55.7%); and
- fasting plasma glucose (FPG; WMD, −1.60 [95% CI, −2.21 to −1.00] mmol/L; I2=88.1%); P<.001 for all.>
- Similar results were observed with empagliflozin 25 mg plus linagliptin 5 mg compared with linagliptin 5 mg or empagliflozin (10 or 25 mg) monotherapy.
- Patients who received empagliflozin (10 or 25 mg) plus linagliptin 5mg were at 3-fold higher likelihood of achieving HbA1c
- No significant difference was observed in adverse events between combination and monotherapy.
- Heterogeneity among studies.